Blog

The Empowerment of the Rare Disease Patient

The stakeholders in healthcare in the developed world are conventionally divided into three ‘P’ words: patients, payers and pharmaceutical companies. In addition, there are a couple of other more minor players, namely physicians and pharmacists. Recent developments have, however, dramatically increased the importance and changed the role of one of these participants, the patient community.

View Details »


Value and cost-based pricing

David Grainger wrote recently on his DrugBaron blog about the pricing of pharmaceuticals. It is an intelligent piece, yet if I may I would like to improve upon it.

View Details »


First-in-class new drug for cachexia

Numedicus is please to note the report from PsiOxus, on the outcome of a Phase II trial of MT-102, or s-pindolol, in cancer cachexia. David Cavalla is inventor of this technology (see EP2094254B1).

View Details »


We need better evidence as a basis for off-label prescriptions

The practice of off-label prescription poses a significant issue for the advocates of evidence-based medicine, given that this area is particularly poorly served by data.

View Details »


Repurposed SSRI is cool, say menopausal women

The recent approval by the FDA of the first non-hormonal product for the treatment of menopausal hot flashes (vasomotor symptoms) in women is interesting for at least two reasons associated with its drug-repurposed basis, one to do with regulation and the other to do with litigation.

View Details »


The Relativistic Nature of Pharmaceutical Safety

Safety and efficacy in medicine is always a balance, and the evidence is increasingly that pharmaceuticals are associated with far more side effects than we currently appreciate. But there are two qualifications regarding safety that are insufficiently appreciated. One is patient group, the other is indication, or therapeutic use. We all know that severe conditions […]

View Details »


New drug repurposing opportunities on Twitter

As of today, Numedicus is instantiating a Twitter feed of new drug repurposing opportunities…see http://twitter.com/numedicus

View Details »


F… Therapeutics: Bringing the F-word back to Pharma

This week’s announcement from Boehringer Ingelheim that it is acquiring, after entry into clinical trials, the key asset of FX125L from Funxional Therapeutics, may perhaps change the language of pharmaceutical discovery.

View Details »


Viewpoint: the case for stricter reimbursement rules

The drug regulatory system is directed towards the approval of new medicines for particular uses, based on clinical trials and other evidence that the product is effective and safe. Yet, once approved, it is in most jurisdictions possible for a doctor to prescribe the product for whatever use s/he sees fit. This is in accordance […]

View Details »


Viewpoint: the case for longer drug exclusivity

I have dealt in the past with an analysis of the decline in patent-based drug exclusivity, pointing out that data exclusivity is becoming increasingly important. However, the time has come to raise the issue more broadly: the case for longer terms of commercial protection, in the interests of better medicines should be heard.

View Details »